The cardiovascular and renal benefits of SGLT-2 inhibitors have been demonstrated in several large randomized clinical trials (RCT) in patients with type 2 diabetes and more recently in patients without type 2 diabetes3. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.